AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 6.9% compared to Amgen's net margin of 15.24%. Amgen's return on equity of 66.87% beat Johnson & Johnson's return on equity of 19.98%.

Amgen has a consensus price target of $316.10, signalling upside risk potential of 2.02%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 5.79%. Given that Johnson & Johnson has higher upside potential than Amgen, analysts believe Johnson & Johnson is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.95%. Johnson & Johnson offers a yield of 3.1% to investors and pays a quarterly dividend of $1.24 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Amgen's net income of $627M is lower than Johnson & Johnson's net income of $3.4B. Notably, Amgen's price-to-earnings ratio is 41.04x while Johnson & Johnson's PE ratio is 27.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.01x versus 4.37x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 6.9% compared to Amgen's net margin of -117.16%. Amgen's return on equity of 66.87% beat Moderna's return on equity of -29.09%.

Amgen has a consensus price target of $316.10, signalling upside risk potential of 2.02%. On the other hand Moderna has an analysts' consensus of $53.09 which suggests that it could grow by 106.34%. Given that Moderna has higher upside potential than Amgen, analysts believe Moderna is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.95%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Moderna quarterly revenues of $956M. Amgen's net income of $627M is higher than Moderna's net income of -$1.1B. Notably, Amgen's price-to-earnings ratio is 41.04x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.01x versus 3.12x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.9% compared to Amgen's net margin of 24.22%. Amgen's return on equity of 66.87% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Amgen has a consensus price target of $316.10, signalling upside risk potential of 2.02%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $914.55 which suggests that it could grow by 49.77%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.95%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Amgen's net income of $627M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Amgen's price-to-earnings ratio is 41.04x while Regeneron Pharmaceuticals's PE ratio is 15.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.01x versus 4.95x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 6.9% compared to Amgen's net margin of --. Amgen's return on equity of 66.87% beat Viking Therapeutics's return on equity of --.

Amgen has a consensus price target of $316.10, signalling upside risk potential of 2.02%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 309.97%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.95%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Viking Therapeutics quarterly revenues of --. Amgen's net income of $627M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Amgen's price-to-earnings ratio is 41.04x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 5.01x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.